Lysine acylation in the hepatic immune microenvironment of MASLD: mechanistic review
This narrative review maps how lysine acylation modifications (lactylation, succinylation, malonylation, β-hydroxybutyrylation, and acetylation) regulate hepatic immune and metabolic responses in MASLD, without providing clinical efficacy data.
| Population | Patients with MASLD/MASH (and preclinical models of metabolic hepatic steatosis) |
|---|---|
| Intervention | Lysine acylation modifications (lactylation, succinylation, malonylation, β-hydroxybutyrylation, acetylation) in hepatocytes, macrophages, hepatic stellate cells, and T cells |
| Comparator | Absence of these modifications or baseline state without MASLD (implicit comparator in cited primary studies) |
| Outcome | Lysine acylation-mediated inflammatory activation (macrophages/Kupffer cells); Histone acylation and inflammatory gene transcription regulation; Hepatic fibrosis (hepatic stellate cell activation); Acylation-mediated hepatocyte lipid accumulation; T-cell reprogramming in the hepatic microenvironment; Acylation biomarker potential in liquid biopsy for MASLD; Progression to MASH and hepatocellular carcinoma |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Lysine acylation-mediated inflammatory activation (macrophages/Kupffer cells) | no quantitative effect size reported; preclinical mechanistic data only | — | Very low | — | |
| Histone acylation and inflammatory gene transcription regulation | no quantitative effect size reported; mechanistic review data only | — | Very low | — | |
| Hepatic fibrosis (hepatic stellate cell activation) | no quantitative effect size reported; preclinical mechanistic data only | — | Very low | — | |
| Acylation-mediated hepatocyte lipid accumulation | no quantitative effect size reported; mechanistic review data only | — | Very low | — | |
| T-cell reprogramming in the hepatic microenvironment | no quantitative effect size reported; mechanistic review data only | — | Very low | — | |
| Acylation biomarker potential in liquid biopsy for MASLD | no quantitative effect size reported; conceptual/proposed only | — | Very low | — | |
| Progression to MASH and hepatocellular carcinoma | no quantitative effect size reported; mechanistic review data only | — | Very low | — |
Context
MASLD affects approximately 30% of adults globally and progresses to steatohepatitis, fibrosis, and hepatocellular carcinoma. Understanding post-translational epigenetic mechanisms regulating hepatic immune cells is relevant for identifying therapeutic targets. Mechanistic reviews such as this synthesize dispersed preclinical evidence but do not substitute clinical trials.
What the study showed
The review compiles predominantly preclinical evidence indicating that alterations in the acyl-CoA pool (acetyl-CoA, succinyl-CoA, malonyl-CoA, lactyl-CoA, β-hydroxybutyryl-CoA) in MASLD modify hepatic immune cell responses via lysine acylation. No clinical efficacy data, effect sizes, or confidence intervals are presented. The review proposes a Level I–IV classification system for acylation targets based on the strength of available functional evidence, but validation criteria have not been prospectively tested.
How it was done
Narrative review (non-systematic); does not specify searched databases, inclusion/exclusion criteria, or PRISMA strategy. Covers five major types of lysine acylation. No meta-analysis, standardized data extraction, or formal risk-of-bias assessment of primary studies.
Effect magnitude
No clinical effect size was calculated or reported. Mechanistic evidence is qualitative and derived from heterogeneous preclinical studies.
Risk of bias
Narrative review without a registered protocol, without formal risk-of-bias assessment (AMSTAR-2 not applied), and without systematic study selection criteria. Most evidence derives from in vitro and animal models; translation to humans is speculative. The author-proposed target classification system (Level I–IV) lacks external validation.
What this study does NOT prove
This review does not prove causality between lysine acylation patterns and MASLD progression in humans. It does not demonstrate efficacy of any acylation-targeted therapeutic intervention.
In clinical practice
No clinical intervention can be recommended based on this review. Clinicians should manage MASLD per current guidelines (lifestyle modification, metabolic control). This review does not alter clinical practice.
Limitations
Narrative review without a registered protocol, without formal risk-of-bias assessment (AMSTAR-2 not applied), and without systematic study selection criteria. Most evidence derives from in vitro and animal models; translation to humans is speculative. The author-proposed target classification system (Level I–IV) lacks external validation.
What is still missing
Clinical trials are needed testing deacylase inhibitors (e.g., SIRT5 or HDAC inhibitors) in MASH patients, with validated histological outcomes (NAS, fibrosis stage) and acylation biomarkers in biopsies or plasma.
Technical appendix
Version history
- 1.0 · 2026-10-22 — Auto-generated under Evidence Standard v1.0